Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
1. A method of delivering a calcium channel inhibitor to a cell that expresses STEAP-1 protein (SEQ ID NO:3), comprising:
providing a calcium channel inhibitor conjugated to an antibody or fragment thereof comprising an antigen binding site that binds specifically to STEAP-1 protein (SEQ ID NO:3), to form an antibody-inhibitor or fragment-inhibitor conjugate; and
exposing the cell to the antibody-inhibitor or fragment-inhibitor conjugate.
2. The method of claim 1 wherein the calcium channel inhibitor is selected from the group consisting of amlodipine, azulene, dihydropyridines, thianines, nifedine, verapamil, nordihydroguaiaretic acid (NDGA), and derivatives thereof.
3. A method of inhibiting the growth of a cancer cell that expresses STEAP-1 protein (SEQ ID NO:3), comprising:
providing a calcium channel inhibitor conjugated to an antibody or fragment thereof comprising an antigen binding site that binds specifically to STEAP-1 protein (SEQ ID NO:3), to form an antibody-inhibitor or fragment-inhibitor conjugate; and
exposing the cell to the antibody-inhibitor or fragment-inhibitor conjugate.
4. The method of claim 3 wherein the calcium channel inhibitor is selected from the group consisting of amlodipine, azulene, dihydropyridines, thianines, nifedine, verapamil, nordihydroguaiaretic acid (NDGA), and derivatives thereof.
5. The method of claim 3 wherein the cancer is metastatic.
6. The method of claim 3 wherein the cancer is prostate, bladder, kidney, colon, lung, pancreatic, ovary, breast, stomach or rectal cancer, or lymphoma.
7. The method of claim 3 wherein the cancer is prostate cancer.
8. A method of inhibiting the activity of STEAP-1 protein (SEQ ID NO:3), comprising:
providing a calcium channel inhibitor conjugated to antibody or fragment thereof comprising an antigen binding site that binds specifically to STEAP-1 protein (SEQ ID NO:3), to form an antibody-inhibitor or fragment-inhibitor conjugate; and
exposing the cell to the antibody-inhibitor or fragment-inhibitor conjugate.
9. The method of claim 8 wherein the calcium channel inhibitor is selected from the group consisting of amlodipine, azulene, dihydropyridines, thianines, nifedine, verapamil, nordihydroguaiaretic acid (NDGA), and derivatives thereof.